Viewing Study NCT00068341



Ignite Creation Date: 2024-05-05 @ 11:31 AM
Last Modification Date: 2024-10-26 @ 9:09 AM
Study NCT ID: NCT00068341
Status: COMPLETED
Last Update Posted: 2020-09-09
First Post: 2003-09-10

Brief Title: Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Sponsor: Jonsson Comprehensive Cancer Center
Organization: Jonsson Comprehensive Cancer Center

Study Overview

Official Title: Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: COMPLETED
Status Verified Date: 2016-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy such as docetaxel and carboplatin use different ways to stop tumor cells from dividing so they stop growing or die Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells It is not yet known whether docetaxel and carboplatin are more effective with or without trastuzumab in treating breast cancer

PURPOSE This randomized phase II trial is studying how well giving docetaxel together with carboplatin and trastuzumab before surgery works compared to docetaxel and carboplatin alone before surgery in treating women with locally advanced breast cancer
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
CDR0000321924 None None None
AVENTIS-GIA-11156 None None None
GENENTECH-H2269s None None None